Compare NTNX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | IBRX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 8.4B |
| IPO Year | 2015 | 2015 |
| Metric | NTNX | IBRX |
|---|---|---|
| Price | $40.87 | $7.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $64.33 | $12.57 |
| AVG Volume (30 Days) | 3.1M | ★ 23.0M |
| Earning Date | 02-25-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 227.45 | 38.71 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,537,927,000.00 | $113,288,000.00 |
| Revenue This Year | $13.60 | $88.59 |
| Revenue Next Year | $13.18 | $131.15 |
| P/E Ratio | $66.75 | ★ N/A |
| Revenue Growth | 18.11 | ★ 668.31 |
| 52 Week Low | $35.39 | $1.83 |
| 52 Week High | $83.36 | $12.43 |
| Indicator | NTNX | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 46.24 |
| Support Level | $35.84 | $5.89 |
| Resistance Level | $42.50 | $8.28 |
| Average True Range (ATR) | 1.70 | 0.94 |
| MACD | 0.06 | -0.21 |
| Stochastic Oscillator | 72.79 | 25.50 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.